Manufactured CAR T cells ready for infusion into a patient.

FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma

The Food and Drug Administration approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that has not responded to or has returned after at least four different prior cancer treatments. The approval is based, in part, on earlier clinical work led by James N. Kochenderfer, M.D., Senior Investigator in the Surgery Branch. Read more...

FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma
Crystals of IgG Antibodies

Clinical trial to test drug for cancer patients with weakened immune systems

Nov 16, 2020

Cancer survivors age 60 and older have weakened immune systems, often caused by cancer treatments. Investigators want to see if a drug, NT-I7, is able to boost the response to vaccines in patients who otherwise may not be able to respond. Read more...

photoimmunotherapy

Japan approves photoimmunotherapy for head and neck cancer

Nov 4, 2020

Promising clinical trials have led to the regulatory approval of the Bioblade® Laser System and Akalux® IV Infusion 250mg in Japan. This device and drug combination was developed under an investigational treatment platform based on a cancer therapy called photoimmunotherapy. Read more...

pancreatic cancer cells

Pancreatic Cancer Research

Nov 2, 2020

November is Pancreatic Cancer Awareness Month. We have many researchers, both in the basic and clinical disciplines, who are working on pancreatic cancer.  Learn more...

Lung cancer cells

Lung Cancer Research

Nov 2, 2020

November is Lung Cancer Awareness Month. Our research portfolio includes investigators making important discoveries in lung cancer research.  Read more...

stem cell transplant

New clinical trial studies stem cell transplant for primary immunodeficiency diseases

Oct 28, 2020

Dennis D. Hickstein, M.D., Senior Investigator in the Immune Deficiency Cellular Therapy Program is leading a study that uses new DNA technology that speeds up the process of screening for primary immunodeficiency diseases (PIDs) and finding an acceptable donor match for hematopoietic stem cell transplant (HSCT). Read more...

Prostate-specific membrane antigen

Clinical trial studies therapy for people with prostate or kidney cancer

Oct 22, 2020

James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading the National Cancer Institute’s participation in a clinical trial of an experimental drug called JNJ-63898081. The goal of this multicenter study is to find out if the drug is safe to use in humans and to determine the optimal dose for the second phase of the study. Read more...

Combination therapy tested in clinical trial for metastatic genitourinary cancers

Oct 20, 2020

Genitourinary cancers are common but difficult to treat with chemotherapy or immunotherapy alone. A new clinical trial studies two drugs that intensify the immune system’s attack on cancer cells. Read more...

NAM logo

Peter Choyke and Louis Staudt elected to the National Academy of Medicine

Oct 19, 2020

Peter Choyke, M.D., F.A.C.R., Chief of the Molecular Imaging Branch, and Louis Staudt, M.D., Ph.D., Chief of the Lymphoid Malignancies Branch, have been elected to the National Academy of Medicine (NAM). Dr. Choyke is elected for pioneering advances in the imaging of prostate cancer that have enabled accurate localization of clinically significant tumors. Dr. Staudt is elected for demonstrating that genetic profiling can distinguish lymphoma subtypes, predict patient survival, and individualize therapy, thus playing a key role in launching the era of cancer precision medicine. Read more...

Lymphoma mass before and after treatment

Phase 1 CAR T-cell therapy leads to years-long remissions in relapsed B-cell lymphoma patients

Oct 13, 2020

In a Journal of Clinical Oncology article, results of a phase 1 trial by CCR investigators show that CAR T-cell therapy can result in long-lasting remissions in patients with certain relapsed B-cell lymphomas. Many who had life expectancies of only six months or less during the clinical trial of the therapy, which spanned from 2009 to 2015, remain in complete remission. Read more...

HPV-16 E5 Oncoprotein

Clinical trial tests immunotherapy combination for advanced HPV-associated cancers

Oct 13, 2020

Human papillomavirus (HPV) is the most common sexually transmitted infection. More than 30,000 cases of HPV+ cancers occur every year in the United States. CCR investigators are leading a study using a combination of 3 immunotherapy drugs to treat HPV+ cancers. Read more...

Pages